All In Biotech

Drug Trial Radar · NCT06550895

A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma

A Phase 2, Open-Label, Multicenter Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

11

Actual

Start

Sep 16, 2024

Primary completion

Aug 26, 2027

Study completion Aug 26, 2027

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Aug 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to define the safety of Ciltacabtagene Autoleucel (Cilta-cel) and Talquetamab in participants with high-risk multiple myeloma (MM).

Conditions

  • Multiple Myeloma

Interventions

  • Cilta-celDrug

    Cilta-cel infusion will be administered intravenously.

  • TalquetamabDrug

    Talquetamab will be administered subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AE) by Severity According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0Time frame: Up to 3 years and 5 months

Locations

9 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Iowa Hospital and Clinics

    Iowa City, Iowa

  • Norton Cancer Institute

    Louisville, Kentucky

  • Barbara Ann Karmanos Cancer Institute

    Detroit, Michigan

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Royal Prince Alfred Hospital

    Camperdown, Australia

  • Austin Hospital

    Heidelberg, Australia

  • Peter MacCallum Cancer Centre

    Melbourne, Australia

  • The Alfred Hospital

    Melbourne, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.